Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311350 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects
A Phase 1 study of Constipation and Postoperative Complications, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00311350 is a Phase 1 study of Constipation and Postoperative Complications that has completed, run by Bausch Health Americas. The registered enrollment target is 48 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00311350, a Phase 1 study of Constipation and Postoperative Complications, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.
Conditions Studied
Interventions
- DRUG MOA-728
Study Locations (1)
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311350
The ClinicalTrials.gov registry entry for NCT00311350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (77% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which MOA-728 is the first listed.
NCT00311350 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00311350 about?
NCT00311350 is a clinical study titled "Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects". This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.
What is the current status of trial NCT00311350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-03. Estimated completion is 2006-08.
What conditions does trial NCT00311350 study?
This clinical trial studies the following conditions: Constipation, Postoperative Complications.
What interventions are being tested in trial NCT00311350?
The interventions under investigation include: MOA-728 (DRUG).
Who is sponsoring clinical trial NCT00311350?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00311350 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
COMPLETED · Phase 1
-
Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI
COMPLETED · Phase 1
-
A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.